Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 6, 2019European Respiratory ReviewOpen Access

Management of pulmonary toxicity associated with immune checkpoint inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMyriam DelaunayClinique Saint Jean LanguedocGPGrégoire PrévôtUniversité Fédérale de Toulouse Midi-PyrénéesSCS. CollotUniversité Fédérale de Toulouse Midi-Pyrénées

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Delaunay et al. (2019) studied this question.

synapsesocial.com/papers/6a5cc89d32bc51c568c4e017https://doi.org/10.1183/16000617.0012-2019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L12016 · 285 citations
  2. 2Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders2015 · 661 citations
  3. 3Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck2016 · 5,208 citations
  4. 4An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias2013 · 4,356 citations
  5. 5Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event2018 · 72 citations